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Abstract
Background: The semaphorins and their receptors, the plexins, are proteins related to c-Met and the scatter factors that
have been implicated in an expanding signal transduction network involving co-receptors, RhoA and Ras activation and
deactivation, and phosphorylation events. Our previous work has demonstrated that Semaphorin 4D (Sema4D) acts through
its receptor, Plexin-B1, on endothelial cells to promote angiogenesis in a RhoA and Akt-dependent manner. Since NF-kB has
been linked to promotion of angiogenesis and can be activated by Akt in some contexts, we wanted to examine NF-kBi n
Sema4D treated cells to determine if there was biological significance for the pro-angiogenic phenotype observed in
endothelium.
Methods/Principal Findings: Using RNA interference techniques, gel shifts and NF-kB reporter assays, we demonstrated NF-
kB translocation to the nucleus in Sema4D treated endothelial cells occurring downstream of Plexin-B1. This response was
necessary for endothelial cell migration and capillary tube formation and protected endothelial cells against apoptosis as
well, but had no effect on cell proliferation. We dissected Plexin-B1 signaling with chimeric receptor constructs and
discovered that the ability to activate NF-kB was dependent upon Plexin-B1 acting through Rho and Akt, but did not involve
its role as a Ras inhibitor. Indeed, inhibition of Rho by C3 toxin and Akt by LY294002 blocked Sema4D-mediated endothelial
cell migration and tubulogenesis. We also observed that Sema4D treatment of endothelial cells induced production of the
NF-kB downstream target IL-8, a response necessary for angiogenesis. Finally, we could show through co-
immunofluorescence for p65 and CD31 that Sema4D produced by tumor xenografts in nude mice activated NF-kBi n
vessels of the tumor stroma.
Conclusion/Significance: These findings provide evidence that Sema4D/Plexin-B1-mediated NF-kB activation and IL-8
production is critical in the generation a pro-angiogenic phenotype in endothelial cells and suggests a new therapeutic
target for the anti-angiogenic treatment of some cancers.
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Introduction
The semaphorins are a family of secreted, transmembrane and
glycosylphosphatidylinositol-linked proteins characterized by large
cysteine-rich semaphorin domains that were originally identified
based on their ability to provide both attractive and repulsive axon
guidance cues during neural development [1]. They are now
known to be expressed in tissues outside of the nervous system
where they are involved in many motility responses including
regulation of cell-cell contacts and branching morphogenesis in
epithelium [2], promotion of angiogenesis [3,4], and growth and
metastasis of tumors [5,6]. The main functional receptors for
semaphorins are a family of single pass transmembrane proteins
known as plexins [7,8]. The intracellular portion of the plexins
contain a GTPase-activating protein (GAP)-like motif that
downregulates activity of the G protein R-Ras, interrupted by a
region capable of binding small Rho family GTPases [9,10]. In the
case of Plexin-B1 for example, this Rho GTPase binding domain
(RBD) can associate with Rnd1, Rac1, and RhoD, the binding of
which influences plexin functioning [10]. The small GTPases act
as molecular switches that cycle between an active GTP-bound
and inactive GDP-bound form to regulate microtubule dynamics,
cell shape and cell mobility [11]. Therefore, it is likely that the
binding of semaphorins to plexins initiates a signaling cascade that
impinges upon the cytoskeleton [12]. In addition to the small
GTPases, kinase activity plays a vital role in plexin signaling. The
plexins themselves are devoid of any intrinsic kinase activity, so
this function is provided by kinases activated by the signaling
complex, depending upon the class of plexins and the context.
The nuclear factor (NF)-kB family of transcription factors plays
an important role in the ability of a cell to adapt to environmental
changes and figures prominently in many biological processes. NF-
kB dimers positively or negatively regulate expression of target
genes in response to bacterial products, cytokines, viral infection,
growth factors and other stressful stimuli [13]. In the inactive form,
NF-kB is bound to the inhibitor of kB (I-kB) family of proteins that
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kB kinase (IKK) complex phosphorylates the I-kB proteins on two
conserved N-terminal serine residues, which target them for E2-
and E3-ligase-mediated polyubiquitination and subsequent 26S
proteasomal degradation [14]. This process releases and activates
NF-kB, freeing it up to move to the nucleus where it undergoes a
series of posttranslational modifications and binds to specific DNA
sequences in target genes (designated as ‘‘kB elements’’) that
regulate the transcription of over 500 genes involved in
inflammation, the immune response, cell growth control and the
regulation of cell survival [14]. Importantly, dysregulated NF-kB
activity has been associated with tumor promotion, suppression of
apoptosis, tumor-induced angiogenesis and metastasis [15].
Our lab and others have shown that Semaphorin 4D (Sema4D)
is pro-angiogenic when acting through its receptor Plexin-B1 on
endothelial cells [3,4] and may be produced by malignancies for
the purposes of promoting blood vessel growth into the tumor
[16]. There is a PDZ binding motif at the C-terminus of Plexin-B1
that associates with PDZ-Rho guanine nucleotide exchange factor
(GEF) and leukemia-associated RhoGEF (LARG), proteins that
activate Rho [17,18]. Sema4D binding to Plexin-B1 also promotes
Rnd1-dependent activation of receptor GAP activity and R-Ras
inhibition [9,10]. Finally, there is evidence that Plexin-B1
competes with p21-activated kinase (PAK) for Rac binding,
sequestering the active form of Rac and inhibiting Rac-dependent
processes [19]. We previously have demonstrated that pro-
angiogenic Plexin-B1 signaling is dependent upon its ability to
activate Rho, specifically by signaling through the downstream
effector Rho kinase (ROK) and activating Akt, Src and Pyk2 [20].
Since NF-kB has been linked to promotion of angiogenesis in
some malignancies [21] and IKK can be phosphorylated by Akt,
leading to activation of NF-kB [22], we wanted to examine NF-kB
in response to Plexin-B1 stimulation and determine if there was
any biological significance for the pro-angiogenic phenotype
observed in endothelial cells. Here we show that NF-kB and its
pro-angiogenic effector IL-8 are activated downstream of Plexin-
B1. In endothelial cells, this response occurred following treatment
with Sema4D and was necessary for chemotaxis, capillary tube
formation and resistance to apoptosis. We could elicit NF-kB
activation in endothelial cells when treated by conditioned media
from head and neck squamous cell carcinoma (HNSCC) cell lines
expressing Sema4D and demonstrate activation of NF-kB in vivo in
a tumor xenograft model. Taken together, these results demon-
strate further versatility in plexin signaling that may hint at new
diagnostic and therapeutic approaches in the anti-angiogenic
treatment of some cancers.
Results
Sema4D activates NF-kB through Plexin-B1
Though Sema4D is also known to bind to lower-affinity
receptors such as CD72 (on cells of hematopoietic origin, which
include endothelial cells) [23] and Plexin-B2 (which has only been
observed in neurons) [24], we previously have demonstrated that
promotion of a pro-angiogenic phenotype in endothelial cells is
due to ligation by Sema4D of its high-affinity receptor, Plexin-B1
[4], which in turn activates Akt [25]. The pro-inflammatory and
pro-cell survival protein NF-kB is a known functional target of Akt
[22,26] and has been linked to angiogenesis. Therefore, we wanted
to look for Plexin-B1-mediated NF-kB activation in Sema4D
treated endothelial cells. NF-kB is sequestered in the cytoplasm by
I-kB, which needs to be phosphorylated and degraded to allow
NF-kB to translocate to the nucleus, so rapid phosphorylation and
loss of I-kB signal in an immunoblot (and then recovery, as I-kBi s
induced by NF-kB) is a good marker for activation of NF-kB. To
determine the role of Plexin-B1 in the activation of NF-kB, we
infected HUVEC with control lentivirus or lentivirus coding for
Plexin-B1 shRNA and confirmed protein knockdown in an
immunoblot (Figure 1A). We then treated these cells with
400 ng/ml Sema4D and observed I-kB phosphorylation
(Figure 1B, upper panel, left) and degradation (Figure 1B, middle
panel, left), but loss of this response in cells expressing reduced
levels of Plexin-B1 (Figure 1B, right panels). We treated control
cells and those infected with Plexin-B1 shRNA-expressing
lentivirus with soluble Sema4D, lysed them and incubated the
nuclear fraction with labeled oligonucleotides containing kB
elements to look for binding in an electrophoretic mobility shift
assay. NF-kB binding was detected by a gel shift in Sema4D
treated cells but not in cells infected with Plexin-B1 shRNA
(Figure 1C). Specificity of this assay was demonstrated by a
supershift upon incubation with a p65 antibody and a loss of signal
when incubated with a 100-fold excess of unlabelled oligonucle-
otide (Figure 1C). We also detected the NF-kB subunit p65
migrating to the nucleus in an immunofluorescence analysis of
Sema4D treated HUVEC (Figure 1D) and in an immunoblot of
nuclear and cytoplasmic fractions from these cells (Figure 1E). We
then looked for NF-kB activation in a reporter assay in HUVEC
expressing an NF-kB responsive luciferase construct, following
treatment with Sema4D. We observed a concomitant increase in
fluorescence with increasing concentrations of Sema4D
(Figure 1F). Taken together, these results demonstrate that
Sema4D induces NF-kB translocation to the nucleus and
transcriptional activity in endothelial cells in a Plexin-B1-
dependent manner.
Sema4D induces a pro-angiogenic phenotype and
apoptotic protection in endothelial cells through NF-kB
but has no effect on proliferation or VEGF-mediated
angiogenesis
To determine the biological significance of the activation of NF-
kB we observed in endothelial cells, we performed a Boyden
chamber migration assay on HUVEC, as an in vitro measure of
angiogenesis, with and without the NF-kB inhibitor BAY11-7085
and an I-kB mutant protein resistant to phosphorylation and
degradation (the ‘‘super-repressor’’), using Sema4D as the
chemoattractant. HUVEC migrated towards Sema4D, as we
and others have observed before [3,4], except when co-treated
with BAY11-7085 (Figure 2A), and where cells were infected with
lentiviruses coding for the I-kB super-repressor (Figure 2B, results
quantified for both migration assays in the bar graph, lower
panels). HUVEC continued to migrate towards FBS in both
instances, indicating the specificity of NF-kB activation in
Sema4D-mediated chemotaxis. We also looked for the ability of
these cells growing on reconstituted basement membrane material
to form tube-like capillary structures in tissue culture under similar
conditions, which is indicative of a pro-angiogenic response.
HUVEC formed capillary tubes when growing on reconstituted
basement membrane material in the presence of Sema4D except
when co-treated with BAY11-7085 (Figure 2C) or when expressing
the I-kB super-repressor (Figure 2D, results quantified for both
tubulogenesis assays in the bar graph, lower panels). NF-kB is also
known to promote cell survival and proliferation in different cell
lines. In order to determine the effects of Sema4D-mediated
activation of NF-kB on endothelial cell survival, we treated
HUVEC with soluble Sema4D and looked for resistance to
apoptosis under conditions of serum starvation, with or without
the NF-kB inhibitor BAY 11-7085. We noted the presence of
Plexin-B1 Activates NF-kB and IL-8
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25826cleaved, and hence activated, caspase 3 in serum starved cells, a
response which decreased in increasing concentrations of Sema4D
but returned when the cells were co-treated with BAY 11-7085,
indicating that this effect was dependent upon Sema4D-induced
NF-kB activity (Figure 2E). To evaluate if endothelial cell
proliferation is enhanced by Sema4D, we measured HUVEC
proliferation by [
3H] thymidine incorporation assay, using
vascular endothelial growth factor (VEGF) treatment as a positive
control. As expected, VEGF treated HUVEC were stimulated to
proliferate, incorporating [
3H] at three times the rate of controls
(Figure 2F). Interestingly, no concentrations of Sema4D seemed to
influence HUVEC proliferation (Figure 2F).
Because we noted endothelial cell proliferation in the presence
of VEGF but not Sema4D, we suspected that these two pro-
angiogenic factors elicited different signaling pathways and
possibly functioned independently of each other. To further
establish their independence and evaluate the role of Sema4D and
Plexin-B1 in the broader context of the angiogenic process, we
Figure 1. Sema4D activates NF-kB downstream of Plexin-B1. A. Immunoblot analysis for Plexin-B1 on lysates from endothelial cells infected
with empty vector control lentivirus (control) or virus coding for Plexin-B1 shRNA (PB1shRNA). GAPDH was used as a loading control (lower panel). B.
Immunoblot for phospho- and total I-kB (upper and middle panels, respectively) in endothelial cells infected with empty vector control lentivirus
(control, left column) or virus coding for Plexin-B1 shRNA (PB1shRNA, right column) treated with Sema4D for the times indicated. GAPDH was used as
a loading control (lower panels). C. EMSA performed on control infected HUVEC or cells infected with lentivirus coding for Plexin-B1 shRNA, in the
presence of Sema4D with and without competition from unlabeled oligos (competition) or anti-p65 antibody (p65 antibody). ‘‘ns’’ denotes a non-
specific band; ‘‘NF-kB’’ indicates a shift in oligo migration; ‘‘supershift’’ indicates the higher band resulting from antibody binding. D.
Immunofluorescence for the presence of the p65 subunit of NF-kB in nuclei of HUVEC, controls (top row) or treated with Sema4D (bottom row). p65
is shown in green (center column). DAPI was used to stain cell nuclei (left column). The merged image is shown in the right column. E. Immunoblot
for the presence of p65 in cytoplasmic and nuclear fractions of HUVEC treated with Sema4D. GAPDH was used as a loading control (lower panel). F.
HUVEC were infected with lentiviruses coding for an NF-kB reporter construct and fluorescence measured in arbitrary units (AU) in increasing
concentrations of Sema4D, as indicated. Error bars represent the standard deviation from three experiments.
doi:10.1371/journal.pone.0025826.g001
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without silenced Plexin-B1, in the presence of Sema4D and
VEGF, and compared the responses. Sema4D and VEGF induced
robust endothelial cell migration compared to control populations
(Fig. 2G). Sema4D-mediated cell migration was greatly reduced in
cells infected with lentiviruses expressing Plexin-B1 shRNA, while
migration toward VEGF remained unaffected (Figure 2G, results
quantified in the bar graph, lower panel). We then confirmed these
results in a tubulogenesis assay, growing endothelial cells on
reconstituted basement membrane extract under the same
conditions. Once again, HUVEC formed capillary tube-like
structures when growing in the presence of Sema4D except when
infected with Plexin-B1 shRNA-expressing lentivirus, while cells
growing in VEGF formed these structures regardless of their
Plexin-B1 status (Figure 2H, results quantified in the bar graph,
lower panel).
Taken together, these findings indicate that NF-kB activation is
necessary for the Sema4D-mediated pro-angiogenic phenotype in
endothelial cells. This response is probably due to endothelial cell
chemotaxis and differentiation into capillary structures and not
due to an effect on cell proliferation, unlike what was observed for
VEGF. Furthermore, insensitivity of endothelial cells to Plexin-B1
status in the presence of VEGF suggests that Sema4D and VEGF
work through independent, parallel pathways to achieve their
respective pro-angiogenic responses.
RhoA and Akt are necessary for Plexin-B1-mediated
activation of NF-kB and promotion of endothelial cell
migration and tube formation by Sema4D
To dissect the pathways involved in Plexin-B1-mediated NF-kB
activation, and to rule out involvement of CD72 or Plexin-B2 in
this process, we looked for phosphorylation and degradation of I-
kB in cells expressing plasmids coding for the chimeric receptors
TrkA fused to full length Plexin-B1, Plexin-B1 lacking the C-
terminal PDZ binding domain necessary to activate Rho, and a
chimera containing Plexin-B1 with mutations at the arginine
residues required for R-RasGAP activity [4,17]. We have
previously shown that we could isolate and study Plexin-B1
specific signaling in cells expressing these constructs when treated
with NGF [4,17]. We also co-treated with the Rho inhibitor C3
toxin or the PI3K inhibitor LY294002, where indicated, in order
to clarify further the role of Ras, Rho and Akt in the NF-kB
response. Phosphorylated I-kB was observed in control treated
cells transfected with the full-length chimera, which was then
rapidly degraded as expected (Figure 3A). However, this response
was absent in cells expressing the full-length chimera but
incubated with C3 or LY294002 and in all cells expressing the
DPDZ chimera incapable of activating Rho (Figure 3A). The R-
RasGAP mutant was still able to elicit phosphorylation and
degradation of I-kB except when co-treated with C3 or
LY294002, indicating that this effect was independent of R-
RasGAP activity (Figure 3A). To further confirm the role of Rho
and Akt in this process, we looked for activation of NF-kB
transcription in a reporter assay in HUVEC transfected with an
NF-kB responsive luciferase construct, treated with Sema4D with
and without C3 or LY294002. Fluorescence was greatly increased
in Sema4D treated HUVEC except when co-treated with C3 or
LY294002 (Figure 3B). We then evaluated the ability of HUVEC
to exhibit chemotaxis or form capillary tube structures in Sema4D,
with or without Rho and Akt inhibition. HUVEC migrated
towards Sema4D, a response that was blocked by C3 and
LY294002 (Figure 3C, results quantified in the bar graph, lower
panel), and could form tubes on reconstituted basement
membrane material in the presence of Sema4D except when co-
incubated with C3 or LY294002 (Figure 3D, results quantified in
the bar graph, right panel). Taken together, these results indicate
that Plexin-B1 activates NF-kB in a Rho and Akt-dependent
manner, and that this pathway needs to remain intact for
Sema4D-mediated promotion of angiogenesis.
Sema4D treatment of HUVEC activates the NF-kB
downstream target IL-8, which is necessary for the
promotion of angiogenesis
We performed an ELISA on media conditioned by Sema4D
treated HUVEC, looking for the presence of IL-8, a known pro-
angiogenic downstream target of NF-kB [27]. HUVEC treated
with increasing concentrations of soluble Sema4D produced
increasing amounts of IL-8, unless when co-treated with the NF-
kB inhibitory compound BAY11-7085 (Figure 4A). To determine
the biological significance of NF-kB-mediated IL-8 production, we
performed a migration assay on HUVEC toward Sema4D, with
and without the presence of IL-8 blocking antibody. As expected,
Sema4D attracted HUVEC, but this response was attenuated by
increasing concentrations of IL-8 blocking antibody (Figure 4B,
results quantified in the bar graph, lower panel). Sema4D-induced
tube formation in HUVEC growing on reconstituted basement
membrane material was also reduced by co-administration of IL-8
blocking antibody (Figure 4C, results quantified in the bar graph,
Figure 2. Sema4D induces migration, capillary tube formation and apoptotic protection in endothelial cells in an NF-kB-dependent
manner, but has no effect on endothelial cell proliferation or VEGF-mediated angiogenesis. A. Migration assays on HUVEC towards BSA,
FBS or Sema4D in the presence of control media or media containing BAY11-7085 (BAY). B. Migration assays on HUVEC, control infected (C), or
infected with the I-kB super-repressor (SR) towards BSA, FBS or Sema4D. C. HUVEC treated with vehicle control (neg ctrl), or BAY11-7085 (BAY), with
or without Sema4D were grown on reconstituted basement membrane material in serum free media and examined for formation of capillary tubes.
Representative photographs are shown. D. HUVEC mock electroporated (mock), or electroporated with the I-kB super-repressor (SR) were grown on
reconstituted basement membrane material in serum free media with or without Sema4D and examined for formation of capillary tubes.
Representative photographs are shown. E. Immunoblot performed for the cleaved fragment of caspase 3 (top panel) in HUVEC growing under
conditions of low serum concentration, treated with the indicated concentrations of Sema4D with or without the NF-kB inhibitory compound BAY11-
7085 (BAY). GAPDH was used as a loading control (lower panel). F. An [
3H] thymidine incorporation assay was performed on HUVEC growing in the
presence of Sema4D or VEGF for the purposes of measuring proliferation. Counts per minute (cpm) are represented on the Y-axis. Error bars represent
the standard deviation from four independent experiments. G. Migration assay on HUVEC, control infected (control), or infected with lentiviruses
expressing Plexin-B1 shRNA (Plexin-B1 shRNA) towards BSA, Sema4D or VEGF. For all migration assays, the results are quantified by the bar graphs in
the bottom panels as the pixel intensity of scanned migration assay membranes, which are shown on the top. Error bars represent the standard
deviation from six wells (*, p,0.05; n.s., not significant). H. HUVEC, control infected (control), or infected with lentiviruses expressing Plexin-B1 shRNA
(Plexin-B1 shRNA) were grown on reconstituted basement membrane material in serum free media with BSA, Sema4D or VEGF and examined for
formation of capillary tubes. Representative photographs are shown. Quantification of the results of all tubulogenesis assays are shown in the bar
graphs in the lower panels, with the Y-axis representing tube formation as measured by summing the length of capillary tubular structures observed
in 10 microscopic fields, relative to the negative control wells (error bars represent the standard deviation from three independent experiments;
*, p,0.05; n.s., not significant).
doi:10.1371/journal.pone.0025826.g002
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tube formation. A. Immunoblot for phospho-I-kB (top panel) and total I-kB (middle panel) in cells expressing chimeric receptors coding for the
extracellular portion of Trk-A fused to the wild-type intracellular segment of Plexin-B1 (wtPB1), Plexin-B1 lacking the PDZ binding motif (DPDZ) or
Plexin-B1 mutated in the RasGAP domain (RasGAP mut), treated with NGF with and without the Rho inhibitor C3 toxin (C3) and the PI3K inhibitor
LY294002 (LY), for the times indicated. GAPDH was used as a loading control (lower panel). B. NF-kB reporter assay performed on control treated
HUVEC or HUVEC treated with Sema4D, with or without C3 toxin or LY294002 (LY), with fluorescence expressed as arbitrary units (AU). Error bars
represent the standard deviation from three experiments. C. Migration assays on HUVEC towards BSA or Sema4D in the presence of control media, or
media containing C3 or LY294002 (LY). Quantification of migration is shown in the bar graph in the lower panel. Error bars represent the standard
deviation from six wells (*, p,0.05). D. HUVEC were plated on reconstituted basement membrane material in serum free media and treated with
vehicle control (control) or Sema4D, with or without co-treatment with C3 toxin (C3) or LY294002 compound (LY), and examined for formation of
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production is necessary for Sema4D to promote a pro-angiogenic
response in endothelial cells.
NF-kB is activated in endothelium by Sema4D-expressing
tumor cells
We have previously shown that many different solid tumors
produce Sema4D for the purposes of inducing angiogenesis [16].
Therefore, we wanted to determine if Sema4D production by
tumor cells could activate NF-kB in endothelial cells. We infected
the HNSCC cell line HN13 with control lentivirus or lentivirus
coding for Sema4D shRNA and confirmed protein knockdown in
an immunoblot (Figure 5A). We then treated HUVEC with media
conditioned by these cell lines and looked for phospho- and total I-
kB levels in an immunoblot. A phospho-I-kB response and I-kB
degradation was noted in HUVEC treated with media condi-
tioned by control infected HN13 but not in HUVEC treated with
media conditioned by Sema4D shRNA infected cells (Figure 5B).
To further determine biological significance in vitro, we looked for
the presence of the p65 NF-kB subunit in the nuclei of endothelial
cells lining blood vessels from the tumor stroma of HN13
xenografts implanted into the flanks of nude mice, either control
infected or infected with Sema4D shRNA-expressing lentivirus.
We observed the presence of p65 in the nuclei of endothelial cells
of blood vessels associated with tumors comprised of control
infected cells, but less so from the vessels associated with tumors
made up of Sema4D shRNA infected cells (Figure 5C). These
results are quantified in Figure 5D. Taken together, these results
strongly suggest that Sema4D production by tumors activates NF-
kB signaling in endothelial cells via Plexin-B1 in order to promote
tumor-induced angiogenesis.
Discussion
Most cancers arise from an altered pre-malignant progenitor
cell that accumulates genetic damage over time, a factor that
contributes to the ability of tumor cells to proliferate inappropri-
ately, avoid natural defenses and acquire resistance to chemo-
therapy. For this reason, patients often are poor candidates for
treatment with traditional cytoreductive therapies but might
benefit from the development of anti-angiogenic agents, which
instead target the normal, genetically stable endothelial cells that
line the vessels that feed the tumor. Indeed, growth and metastasis
of solid tumors requires induction of angiogenesis, the creation and
remodeling of new blood vessels from a pre-existing vascular
network, to ensure the delivery of oxygen, nutrients and growth
factors to rapidly dividing transformed cells.
VEGF is an endothelial cell specific growth factor that plays a
unique role in the regulation of vascular permeability and
physiological and pathological angiogenesis, mainly by acting
through its receptor VEGF-receptor 2 (VEGF-R2) on endothelial
cells. Many different solid tumors have been shown to produce
VEGF, and it has become a tempting target for neutralizing
antibodies in the treatment of advanced neoplasms. We have
demonstrated that Sema4D is over expressed by many different
aggressive carcinomas in a manner analogous to VEGF, and that
its activity on Plexin-B1-expressing endothelial cells promotes
angiogenesis in vitro and in vivo [4]. However, the mechanisms of
Plexin-B1 signaling continue to be investigated. Our group and
others have found that Plexin-B1 activates downstream kinases
such as Akt and triggers a G-protein response in Sema4D treated
cells [4,17,18]. Though the role of NF-kB activation by Akt
remains controversial [28], here we show that stimulation of
Plexin-B1 signaling induces a Rho and Akt-dependent activation
of NF-kB. This effect is independent of the RasGAP activity of
Plexin-B1, as a RasGAP mutant receptor construct was still able to
induce phosphorylation and degradation of I-kB. It is also a purely
Plexin-B1-mediated response and likely does not involve the low-
affinity Sema4D receptors CD72 or Plexin-B2 or any components
of VEGF signaling, as RNA interference directed at Plexin-B1
blocked Sema4D-mediated NF-kB activation and promotion of a
proangiogenic response while having no effect on HUVEC
responses to VEGF. Furthermore, stimulation of Plexin-B1 specific
signaling through NGF-mediated activation of TrkA/Plexin-B1
chimeric receptors promoted I-kB phosphorylation and degrada-
tion.
NF-kB is known to be a crucial mediator of inflammation-
induced tumor growth and progression, as well as a strong
promoter of oncogenesis and tumor cell survival [29] but its effects
in endothelial cells on the promotion of angiogenesis is not well
studied. There is conflicting evidence in the literature demon-
strating that NF-kB activation can be both pro- and anti-
angiogenic, mainly by influencing endothelial cell apoptosis
[30,31]. In our system, we show that NF-kB activation by
Sema4D results in promotion of endothelial cell survival,
migration and tube formation, but unlike VEGF fails to induce
significant cell proliferation. These results led us to speculate that
Sema4D might elicit a parallel but slightly more limited
angiogenic repertoire in endothelial cells when compared to
VEGF. However, we also observed robust Sema4D-dependent
stimulation of IL-8. This is a significant finding, as IL-8 is secreted
by a variety of cells, including endothelial cells, and plays
important roles in inflammation and tumor-induced angiogenesis
[21]. Many reports have identified NF-kB as the main
transcription factor for stimulating IL-8 promoter activity in
response to various stimuli [32]. Our study confirmed that the NF-
kB inhibitor BAY 11-7085 abrogated the release of IL-8 induced
by Sema4D. Stimulation of the NF-kB/IL-8 axis by Sema4D was
crucial, since its blockade attenuated the pro-angiogenic response.
We also looked for evidence that tumor cells making Sema4D
could induce NF-kB activation in endothelium. We showed in vitro
that media conditioned by HNSCC cells could induce I-kB
phosphorylation and degradation in HUVEC in a Sema4D-
dependent manner. In vivo we observed p65 translocation in the
nucleus of endothelial cells in the tumor stroma when tumors were
expressing Sema4D but much less so in vessels associated with
tumors where Sema4D had been silenced by shRNA. Taken
together these findings suggest that NF-kB induction in endothelial
cells is crucial for endothelial cell survival and chemotaxis and that
it is induced by tumors producing Sema4D for the purpose of
promotion of angiogenesis.
There is at least one report of plexins being involved in
activation of NF-kB that also appears to promote cell survival.
Catalano et al. demonstrated that binding of Semaphorin 6D
(Sema6D) to its receptor, Plexin-A1, triggered NF-kB transcrip-
tional activity that supported a pro-survival program in malignant
pleural mesothelioma cells [33]. Interestingly, they discovered that
unlike for the system studied here, Sema6D-induced NF-kB
transcriptional activity was dependent upon Plexin-A1-mediated
phosphorylation of VEGF-R2, which associated with Plexin-A1 in
capillary tubes. Representative photographs are shown. Quantification of the results observed in the tubulogenesis assay are shown in the right panel
(error bars represent the standard deviation from three independent experiments; *, p,0.05).
doi:10.1371/journal.pone.0025826.g003
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whether or not a co-receptor tyrosine kinase or other signaling
protein might be involved in Plexin-B1-mediated activation of NF-
kB, particularly since Plexin-B1 itself cannot act as a tyrosine
kinase. It has been reported that the tyrosine kinase receptor c-Met
cooperates with Plexin-B1 to elicit a Sema4D-mediated signal
[2,3]. Such a possibility is currently being investigated.
In summary, we have provided evidence that Sema4D/Plexin-
B1-mediated NF-kB activation and IL-8 production is critical in
the generation a pro-angiogenic phenotype in endothelial cells,
where it promotes migration and survival. However, further
studies likely will be necessary to investigate the mechanisms of
signaling. Sema4D production by tumors may represent an
alternative angiogenesis pathway and therefore represent another
Figure 4. Sema4D treatment of HUVEC induces NF-kB-dependent production of IL-8, which is necessary to promote angiogenesis.
A. ELISA for production of IL-8 in HUVEC treated with the indicated concentrations of Sema4D or 400 ng/ml Sema4D with BAY11-7085 (BAY). Results
are expressed as averages in pg/ml. Error bars represent the standard deviation for three independent experiments. B. Cell migration assay for HUVEC
migrating towards BSA or Sema4D in the presence of IgG control (IgG) or the indicated concentrations of anti-IL-8 blocking antibody. The results are
quantified in the bar graph below as the pixel intensity of the scanned migration assay membrane. Error bars represent the standard deviation from
six wells (*, p,0.05). C. HUVEC were plated on reconstituted basement membrane material in control media (BSA) or media containing Sema4D, with
IgG control (IgG) or the indicated concentrations of IL-8 blocking antibody and examined for formation of capillary tubes. Representative
photographs are shown. Quantification of the results observed in the tubulogenesis assay are shown in the bar graph below (error bars represent the
standard deviation from three independent experiments; *, p,0.05).
doi:10.1371/journal.pone.0025826.g004
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aggressive cancers.
Materials and Methods
Ethics statement
All animal studies were approved by the University of Maryland
Office of Animal Welfare, Institutional Animal Care and Use
Committee (protocol #: 07-03-01) in accordance with the NIH
Guide for the Care and Use of Laboratory Animals.
Cell culture
Human umbilical vein endothelial cells (HUVEC, ATCC,
Manassas, VA) were cultured in Endothelial Cell Medium-2
(EGM-2, Lonza). 293T (ATCC) cells and HN13 cells [34] were
cultured in DMEM (Sigma, St. Louis, MO) supplemented with
10% fetal bovine serum (unless otherwise indicated) and 100
units/ml penicillin/streptomycin/amphotericin B (Sigma).
Purification of soluble Sema4D
Sema4D was produced and purified as described previously [4].
Briefly, the extracellular portion of Sema4D was subjected to PCR
and the resulting product cloned into the plasmid pSecTag2B
(Invitrogen, Carlsbad, CA). This construct was transfected into
293T cells growing in serum free media. Media containing soluble
Sema4D was collected 65 hours post-transfection and purified
with TALON metal affinity resin (Clontech Laboratories, Palo
Alto, CA) according to manufacturer’s instructions. Concentration
and purity of the TALON eluates was determined by SDS PAGE
analysis followed by silver staining (Amersham Life Science,
Piscataway, NJ) and the Bio-Rad protein assay (Bio-Rad,
Hercules, CA). In all cases, media collected from cells transfected
with the empty pSecTag2B vector were used as control.
Immunoblot analysis
Cells were lysed in lysis buffer (50 mM Tris-HCl, 150 mM
NaCl, 1% NP 40) supplemented with protease inhibitors (0.5 mM
phenylmethylsulfonyl fluoride, 1 ml/ml aprotinin and leupeptin,
Sigma) and phosphatase inhibitors (2 mM NaF and 0.5 mM
sodium orthovanadate, Sigma) for 15 minutes at 4uC. After
centrifugation, protein concentrations were measured using the
Bio-Rad protein assay (Bio-Rad). 100 mg of protein from each
sample was subjected to SDS-polyacrylamide gel electrophoresis
and transferred onto a PVDF membrane (Immobilon P, Millipore
Corp., Billerica, MA). The membranes were then incubated with
the appropriate antibodies. The antibodies used were as follows:
Plexin-B1 (Santa Cruz A8); GAPDH (Sigma); phospho-I-kB
(Santa Cruz, S.C.-101713); total I-kB (Santa Cruz, S.C.-371);
p65 (Neomarkers, Fremont, CA); cleaved caspase 3 (Cell
Signaling, Beverly, MA); Sema4D (BD Transduction Labs, BD
Biosciences, Palo Alto, CA). Proteins were detected using the ECL
chemiluminescence system (Pierce, Rockford, IL). Where indicat-
ed, cells were treated with the indicated concentrations of soluble
Sema4D, C3 toxin (List Biological Laboratories, Campbell,
California), LY294002 (Sigma), LPS (Sigma), or BAY11-7085
(Sigma).
Figure 5. Sema4D produced by tumor cells activates NF-kB in endothelial cells. A. Immunoblot analysis for Sema4D on lysates from HN13
cells, infected with empty vector control lentivirus (control) or virus coding for Sema4D shRNA (S4DshRNA). GAPDH was used as a loading control
(lower panel). B. Immunoblot for phospo- (upper panel) and total (middle panel) I-kB in HUVEC growing in media conditioned by control infected
HN13 cells (control, left column) or cells infected with Sema4D shRNA expressing lentivirus (S4DshRNA, right column) for the times indicated. GAPDH
was used as a loading control (lower panel). C. Immunofluorescence on tumor xenografts composed of control infected HN13 cells or cells infected
with Sema4D shRNA, for CD31 (endothelial cells, red) and p65 (green). The white arrows indicate endothelial cell nuclei. D. The results of the
xenograft immunofluorescence expressed as the percentage of p65 positive endothelial cell nuclei counted in 10 high power fields (*, p,0.05).
doi:10.1371/journal.pone.0025826.g005
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assay (EMSA)
Nuclear extracts were prepared using NE-PER Nuclear and
Cytoplasmic extraction kit (Thermo Scientific, Waltham, MA)
according to the manufacturer’s instructions. EMSAs were
performed with the LightShift chemiluminescent EMSA kit
(Thermo Scientific). DNA-binding probes for NF-kB (forward:
59-GATCGAGGGGACTTTCCCTAGC-39; reverse: 59-GCTA-
GGGAAAGTCCCCTCGATC-39) were annealed and biotin
labeled according to the Biotin 39 End DNA labeling kit (Thermo
Scientific). 20 fM labeled oligonucleotides were added to a 20 ml
reaction mix consisting of 6 mg of nuclear extracts, DNA binding
buffer, Poly (dI-dC), 1% NP-40, and MgCl2 in concentrations
based on manufacturer’s recommendations. For competition
assays, unlabeled oligonucleotides were allowed to bind the
nuclear extracts (30 min at room temperature) before the addition
of labeled probes. Supershift experiments were performed by
incubating 1 mg of the anti NF-kB/p65 antibody (Neomarkers)
with nuclear extract proteins (6 mg for 30 min at room
temperature). The reactions were incubated for additional
20 min with biotin labeled probe. The binding complexes were
separated on 6% native DNA polyacrylamide gel, transferred to a
positively charged nylon membrane (Thermo Scientific) and then
detected using a Chemiluminescent Nucleic acid detection Module
(Thermo Scientific) according to the manufacturer’s instructions
and as previously reported [35].
Immunofluorescence for p65
HUVEC were grown on sterile glass coverslips in 35-mm six-
well plates and treated with 400 ng/ml Sema4D for 60 min. The
cells were washed in PBS, fixed in 3% paraformaldehyde for
15 min, and permeabilized in 0.5% Triton X-100 for 5 min. The
cells were then incubated with anti-p65 antibody (Neomarkers)
diluted 1/200 in PBS with 0.5% BSA at 4uC overnight. After three
more washings with PBS, coverslips were placed in a humidity
chamber for 1 h and covered with FITC-conjugated anti-rabbit
secondary antibody (Sigma, 1:200 dilution in PBS with 0.5% fetal
bovine serum). Coverslips were inverted and mounted onto glass
slides with Vectashield containing 49,6-diamidino-2-phenylindole
(DAPI, Vector Laboratories, Burlingame, CA) and viewed using a
immunofluorescence microscope.
NF-kB reporter assay
HUVEC were seeded in 96-well plates at a density of 5610
3
cells/well. The following day, the cells were infected with
lentiviruses expressing the NF-kB reporter and renilla control
(SA Biosciences, Frederick, MD) according to the manufacturer’s
instructions. After 24 h, the cells were changed to DMEM
containing 1% FBS and treated with varying concentrations of
Sema4D and the indicated inhibitors (3 mg/ml C3 toxin (List
Biological Laboratories) or 50 mM LY294002 (Sigma)) for 18 h, as
shown. Firefly and renilla luciferase activities were measured using
a Dual-Glo luciferase reporter assay system (Promega, Fitchburg
WI), and the ratio of firefly luciferase/renilla luciferase lumines-
cence was calculated as previously described [36]. Assays were
performed in triplicate and average and standard deviation
calculated.
Short hairpin (sh) RNA and lentivirus infections
The shRNA sequences for human Sema4D and Plexin-B1 were
obtained from Cold Spring Harbor Laboratory’s RNAi library
(RNAi Codex, http://katahdin.cshl.org:9331/homepage/portal/
scripts/main2.pl) [37,38]. The sequences used as PCR templates
for Sema4D shRNA have been previously reported [16]. The
sequence used for Plexin-B1 shRNA was 59- TGC TGT TGA
CAG TGA GCG CGC CCA GTA TGT GGC CAA GAA CTA
GTG AAG CCA CAG ATG TAG TTC TTG GCC ACA TAC
TGG GCA TGC CTA CTG CCT CGG A -39. Oligos were
synthesized (Invitrogen) and cloned into pWPI GW, a Gateway
compatible CSCG based lentiviral destination vector. Viral stocks
were prepared and infections performed as previously reported
[16].
Migration assays
Media containing 10% FBS (positive control), serum free media
containing 0.1% BSA (negative control), or serum free media
containing 400 ng/ml of purified Sema4D or 50 ng/ml VEGF,
where indicated, were placed in the bottom well of a Boyden
chamber to serve as chemoattractants. 50,000 serum starved
HUVEC cells infected with control lentivirus, lentivirus coding for
Plexin-B1 shRNA, electroporated with empty vector or electro-
porated with the I-kB super-repressor plasmid [39] were added to
the top chamber along with the indicated inhibitors (3 mg/ml C3
toxin, 50 mM LY294002, or 10 mM BAY11-7085) or blocking
antibodies (IgG control or 2 mg/ml or 10 mg/ml anti-IL-8
antibody (Lifespan Biosciences)) where indicated. The two
chambers were separated by a PVPF membrane (Osmonics, GE
Water Technologies, Trevose, PA, 8 mm pore size) coated with
10 mg/ml fibronectin (GIBCO, Carlsbad, CA). The migration
assay was then performed as described [20]. Briefly, after 7 h, the
chamber was disassembled and the membrane stained with Diff-
Quick Stain (Diff-Quick, Dade Behring, Deerfield, Illinois), placed
on a glass slide and scanned. Densitometric quantitation was
performed with NIH image software and cell migration expressed
as pixel intensity. Each experiment was performed six times and
average and standard deviation calculated.
Tubulogenesis assays
HUVEC cells infected with control lentivirus, lentivirus coding
for Plexin-B1 shRNA, electroporated with empty vector or
electroporated with the I-kB super-repressor plasmid [39], were
grown in 35 mm plates coated with 150 ml of Cultrex basement
membrane extract (Trevigen, Gaithersburg, MD) and incubated
overnight in serum free DMEM or serum free media containing
400 ng/ml of Sema4D or 50 ng/ml VEGF, with or without
inhibitors or blocking antibody (10 mM BAY11-7085, 3 mg/ml C3
toxin, 50 mM LY294002, or 2 mg/ml or 10 mg/ml anti-IL-8
antibody, where indicated). Cells were then fixed in 0.5%
glutaraldehyde and photographed. Media containing 0.1% BSA
served as the negative control. Quantification of results was
determined using NIH Image, measuring and summing the length
of all tubular structures observed in 10 random fields for three
independent experiments.
[
3H] Thymidine incorporation assay
[
3H] thymidine incorporation assay was performed as described
elsewhere [40]. Briefly, HUVEC were seeded in 24-well culture
plates at 5610
4 cells/well and growth-arrested in serum-free
medium overnight. Cells were left as controls or incubated with
media containing 50 ng/ml VEGF or various concentrations of
Sema4D (100–400 ng/ml) for 24 h. 0.5 mCi of [
3H] thymidine
was added to each well, and the cells were incubated for a further
4 h. The final incorporation of [
3H] thymidine into cells was
measured with a liquid scintillation counter (LS-6500; Beckman
Instruments, Inc., Fullerton, CA) and results of four independent
experiments expressed as average counts-per-minute (cpm) relative
to untreated controls.
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Trk-A/Plexin-B1 fusion proteins were made as previously
described [4]. Briefly, the intracellular portion Plexin-B1, with or
without the PDZ binding motif, was cut out of the plasmid pCEFL
EGFP Plexin-B1 with NheI/NotI and cloned in frame with the N-
terminal extracellular and transmembrane portion of the NGF
receptor Trk-A in the vector pCEFL-myc. A Trk-A/Plexin-B1
mutant lacking key residues involved in RasGAP activity was
generated as previously described [4] using the QuikChange II XL
Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). Muta-
tions were confirmed by sequencing.
IL-8 ELISA
Confluent HUVECs were serum starved for 4 h, then cultured
in serum free medium with or without 100 ng/ml, 200 ng/ml or
400 ng/ml Sema4D or 400 ng/ml Sema4D with 10 mM BAY 11-
7085, where indicated, for 12 h. The culture supernatant was
collected and used to analyze IL-8 by ELISA (Cytokine Core
Facility, University of Maryland School of Medicine). Results are
expressed as the average and standard deviation for three
independent experiments.
Tumor xenografts
2610
6 HN13 cells infected ex vivo with control lentiviruses and
virus coding for Sema4D shRNA were resuspended in 250 mlo f
serum-free DMEM with an equal volume of Cultrex basement
membrane extract (Trevigen) and injected subcutaneously into
nude mice. After tumor growth had been recorded, animals were
sacrificed and tumors were removed and processed for co-
immunofluorescence, as described [41]. Briefly, OCT-embedded
8 mm thick frozen tissue sections were cut onto silanated glass
slides, air-dried, and stored at 280uC. They were then thawed,
hydrated, fixed and washed in PBS. The following antibodies were
used: anti-PECAM (BD Pharmingen; 1:100 dilution); Anti-p65
(Neomarkers, 1:100 dilution); Fluorescein anti-rabbit secondary
and Texas-red anti-mouse secondary (Vector Laboratories; 1:200
dilution).
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